Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.

Couderc JP, Kaab S, Hinterseer M, McNitt S, Xia X, Fossa A, Beckmann BM, Polonsky S, Zareba W.

J Clin Pharmacol. 2009 Jan;49(1):6-16. doi: 10.1177/0091270008325927. Epub 2008 Oct 28.

PMID:
18957528
2.

Torsades de pointes following cardioversion: case history and literature review.

Spearritt D.

Aust Crit Care. 2003 Nov;16(4):144-9. Review.

PMID:
14692159
4.

Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.

Skanes AC, Morton BC, Green MS, Tang AS.

Can J Cardiol. 1997 Apr;13(4):383-6. Review.

PMID:
9141970
5.

Experimental models of torsades de pointes.

Weissenburger J, Davy JM, Chézalviel F.

Fundam Clin Pharmacol. 1993;7(1):29-38. Review.

PMID:
8458600
6.

[Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].

Makai A, Rudas L, Liszkai G, Fazekas T.

Orv Hetil. 2003 Feb 2;144(5):241-7. Review. Hungarian.

PMID:
12647553
7.

Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.

Abi-Gerges N, Philp K, Pollard C, Wakefield I, Hammond TG, Valentin JP.

Fundam Clin Pharmacol. 2004 Apr;18(2):139-51. Review.

PMID:
15066127
8.
9.

Antiarrhythmic drugs and torsade de pointes.

Lazzara R.

Eur Heart J. 1993 Nov;14 Suppl H:88-92. Review.

PMID:
8293758
10.

Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias.

Hoehns JD, Stanford RH, Geraets DR, Skelly KS, Lee HC, Gaul BL.

Pharmacotherapy. 2001 Jul;21(7):871-83. Review.

PMID:
11444585
11.

Understanding drug-induced torsades de pointes: a genetic stance.

Kannankeril PJ.

Expert Opin Drug Saf. 2008 May;7(3):231-9. doi: 10.1517/14740338.7.3.231 . Review.

PMID:
18462182
12.

Probable case of torsades de pointes induced by fluconazole.

Khazan M, Mathis AS.

Pharmacotherapy. 2002 Dec;22(12):1632-7. Review.

PMID:
12495173
13.
14.

Cellular mechanisms underlying the long QT syndrome.

Antzelevitch C, Shimizu W.

Curr Opin Cardiol. 2002 Jan;17(1):43-51. Review.

PMID:
11790933
15.
16.

Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsade de Pointes arrhythmias.

Vos MA, van Opstal JM, Leunissen JD, Verduyn SC.

Pharmacol Ther. 2001 Nov-Dec;92(2-3):109-22. Review.

PMID:
11916532
17.

Drug-induced QT dispersion: does it predict the risk of torsade de pointes?

Shah RR.

J Electrocardiol. 2005 Jan;38(1):10-8. Review.

PMID:
15660342
18.

Drug-induced QT prolongation and proarrhythmia: an inevitable link?

Ahmad K, Dorian P.

Europace. 2007 Sep;9 Suppl 4:iv16-22. Review.

PMID:
17766320
19.

HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications.

Singh M, Arora R, Jawad E.

Am J Ther. 2010 Nov-Dec;17(6):e193-201. doi: 10.1097/MJT.0b013e3181ad3437. Review.

PMID:
19636247
20.

Supplemental Content

Support Center